Is QTTB a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Bempikibart and the path to a registration-directed program, with revenue (ttm) at ~$53.7 million, all of it recognized in the fourth quarter of 2025 and none of it product revenue: it is the derecognition of a ~$55.0 million refund liability from the terminated Horizon collaboration, settled with Amgen on November 7, 2025 for ~553,695 shares. Revenue in the first half of 2026 was ~$0. The bear case rests on the concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. Analysts covering it are spread from $36.00 to $59.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $36.00, +125.4% from the $15.97 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Bempikibart and the path to a registration-directed program. SIGNAL-AA Part B enrolled 33 patients with baseline SALT scores of 50 to 100, dosed 200mg weekly for four loading doses and then every other week through Week 36, with ~36.4% having prior exposure to oral JAK inhibitors. The most optimistic analyst target on QTTB is $59.00, +269.4% from the $15.97 price. That figure is only reachable if this thesis works close to its best case.

The concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. The July data came from an open-label single-arm trial of 33 patients with no placebo control, and the headline numbers rest on a 25-patient mITT population, so eight of the 33 enrolled patients sit outside the primary analysis and the ITT figures are materially lower (~30.3% versus ~40.0% on SALT20); alopecia areata trials have a long history of placebo responses and spontaneous regrowth that a single-arm design cannot separate out. The economics of a future partnership are encumbered, because bempikibart is in-licensed from Bristol-Myers Squibb under a 2019 agreement that entitles BMS to development and regulatory milestones of ~$32 million to ~$49 million per indication for the first three indications, up to ~$215 million of commercial milestones, royalties from mid-single digits to ~10%, and up to ~60% of any sublicense income, a share that falls only as the program advances. Dilution has been continuous and is not finished: the share count went from ~12.9 million at the end of 2025 to ~29.8 million by August 3, 2026 through a February registered direct, a March ATM with Cantor Fitzgerald, a May private placement at $8.00 and the July follow-on at $18.25, there are ~6.1 million pre-funded warrants outstanding on top of that, and the company states plainly that its cash will not carry any program to regulatory approval. Finally, the listing itself has been fragile before, with a May 19, 2025 Nasdaq notice for falling below the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1) that was only cured on the strength of the Q4 2025 accounting gain and subsequent raises, and a stock that ranged from ~$1.62 to ~$23.57 within twelve months is not one where position sizing is a detail. The most pessimistic published target is $36.00, +125.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Q32 Bio is a clinical-stage Waltham biotech built around bempikibart, an anti-IL-7R alpha antibody for alopecia areata, backed by roughly $294 million of post-offering cash.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Bempikibart and the path to a registration-directed program) stalling in the reported numbers rather than in the narrative, the risk above (the concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It develops bempikibart (ADX-914), a fully human antibody that blocks the interleukin-7 receptor alpha chain and therefore suppresses signaling from both IL-7 and TSLP, for severe alopecia areata. It has no approved products, no sales force and no product revenue, and employs about 24 people from offices in Waltham, Massachusetts. The remaining pipeline is thin by design: ADX-914-XL, a half-life-extended version of the same antibody, is preclinical, and the tissue-targeted complement platform (ADX-096 and related molecules) is retained but not funded, described in filings as under evaluation for strategic options.

Because of an accounting reversal, not a sale. In 2022 Q32 received ~$55.0 million from Horizon Therapeutics under a collaboration on bempikibart. When that agreement was terminated in November 2023, the money stayed with Q32 but was reclassified as a refund liability owed against future milestone payments. On November 7, 2025 Q32 issued Amgen (which had acquired Horizon) a one-time grant of ~553,695 shares to extinguish every remaining milestone obligation, so the liability was derecognized and the difference was booked as collaboration revenue in the fourth quarter of 2025. That produced ~$53.7 million of revenue and ~$29.8 million of net income for 2025 with no cash changing hands, and it is the sole reason a screen shows QTTB as profitable.

Q32 reported 36-week topline data in July 2026 from an open-label trial of 33 patients with severe or very severe alopecia areata (baseline SALT scores of 50 to 100), of whom ~36.4% had already been treated with oral JAK inhibitors. In the modified intent-to-treat population the mean SALT score fell ~35.3% from baseline, with ~40.0% (10 of 25) reaching a SALT20 response and ~44.0% (11 of 25) reaching SALT30 and SALT50. Across the full 33-patient intent-to-treat set those figures are ~30.3% and ~33.3%. There was no placebo arm, no serious or Grade 3 or higher treatment-related adverse events were reported, and the off-drug follow-up through Week 52 is still running.